SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout

• CNBC's Jim Cramer called Sellas Life Sciences "a great spec" and gave the biotech stock "two thumbs up" during Mad Money's Lightning Round.
• Investor focus remains on Sellas' Phase 3 Regal trial evaluating GPS in AML patients who achieve remission but are not eligible for stem cell transplant.
• Beyond GPS, investors are also watching SLS009, Sellas' second AML drug, with topline AML data expected later this year.

Shares of Sellas Life Sciences (SLS) climbed 2% in overnight trading heading into Friday after CNBC's Jim Cramer gave the biotech firm a bullish endorsement, adding fresh momentum to a stock that is already drawing investor attention ahead of a closely watched Phase 3 acute myeloid leukemia (AML) data readout.

SLS stock jumped 7% on Thursday, logging its fourth straight session in the green. Meanwhile, shares are also tracking their fifth consecutive weekly gain and their best month in 2026. 

Cramer Gives SLS 'Two Thumbs Up'

During the Lightning Round segment of Mad Money on CNBC, Cramer called Sellas "a great spec" despite acknowledging the company's losses. "This stock is up a great deal. And yet you know it's losing a little money. It's a great spec... I say two thumbs up," Cramer said.

The endorsement stood out since Cramer was notably more cautious on several other stocks discussed during the segment. While he called Joby Aviation "a terrific spec" and reiterated his preference for GE Aerospace, he declined to speculate on EchoStar, expressed uncertainty about Nokia and said investors seeking crypto exposure should buy Bitcoin rather than Strategy. 

All Eyes On SLS Regal Data Nearing The Finish Line

Investor focus remains firmly on Sellas' Phase 3 Regal study, which is evaluating galinpepimut-S (GPS), an immunotherapy targeting the WT1 cancer antigen in AML patients who have achieved a second complete remission but are not eligible for stem cell transplant.

The study recently reached 78 of the 80 events required to trigger final analysis and topline results, leaving investors waiting for the company's most important catalyst.

Recent comments from CEO Angelos Stergiou have also fueled optimism around the upcoming readout. During the company’s participation in a stretch of three conferences, Stergiou said that the trial has continued significantly longer than initially projected. "80 events have not occurred yet, almost 25 months after enrollment completion, which obviously indicates longer survival than projected," Stergiou said.

The company has previously said the study would be considered successful if GPS extends the median overall survival to 12.6 months, versus about 8 months with standard treatment.

Stergiou also said that there is "a good chance" the Phase 3 study could show survival outcomes similar to those in earlier GPS studies and potentially support broader recognition of treatment guidelines in AML. The CEO also said the company is "very bullish," while remaining "very pragmatic."

Why Sellas’ GPS Matters For The Elderly

Ahead of the expected data release, Stergiou also highlighted new real-world AML data from MD Anderson Cancer Center involving elderly patients. According to the CEO, newer chemotherapy combinations are helping more high-risk AML patients achieve remission, but most still fail to reach a stem cell transplant.

"Despite being touted as a 'bridge to transplant,' only 15% of these patients actually made it to an allogeneic stem cell transplant," Stergiou said. He added that the remaining patients face a significant treatment gap and used the findings to reinforce Sellas' thesis around GPS as a maintenance therapy option.

"As the REGAL trial approaches its 80th event, real-world data like this reminds us why our mission is so urgent," Stergiou said. "We aren't just trying to help patients achieve remission; we are working to safely prolong lives."

Sellas’ Second AML Bet

Beyond GPS, investors are also monitoring SLS009, Sellas' selective CDK9 inhibitor that is currently in Phase 2 testing.

Stergiou recently highlighted the drug's activity in difficult-to-treat AML populations, including patients with TP53 mutations and venetoclax-resistant disease. During recent investor conferences, he called SLS009's activity in resistant AML "quite astonishing" and said the company expects topline data later this year.

How Do Retail Traders Feel About SLS?

On Stocktwits, retail sentiment for SLS was ‘bullish’ amid a 50% jump in 24-hour message volumes.

One user said, “$SLS Guess who is coming to dinner? Jim Cramer and all of his followers. Should be good for another 10 million shares. Maybe we catch 11 or 12 tomorrow.”

Another user said, “Cramer doesn’t like the pre-approval bio stocks, but is always big on cancer treatment due to the vast market and his mother died of cancer. He is never going to say “don’t buy” or “sell” because he will always bet on a cancer treatment’s success. He probably will look closer at it now, though.”

A separate trader said, “Would not surprise me that he [Cramer] will put one of his "helpers" on researching the stock for his followers. They will do their own DD and will put in fresh buys to really wake the market up to the new bio giant on the block...Timing for him and SLS will prove to be a very positive move for we longs...Give us $10 on the end....We will be in Double Digits...never to return....Luck to Longs.”

SLS stock has surged 416% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform